Deutsche Effecten- und Wechsel-Beteiligungsges. AG

EANS-News: Sloning BioTechnology and Henkel to Co-Operate in Enzyme Development

@@start.t1@@--------------------------------------------------------------------------------   Corporate news transmitted by euro adhoc. The issuer/originator is solely   responsible for the content of this announcement. --------------------------------------------------------------------------------@@end@@

companies/DEWB investment holding

Puchheim/Düsseldorf, 29 June 2009 (euro adhoc) - Multinational consumer chemicals company Henkel will use Sloning BioTechnology´s proprietary protein engineering platform in their Laundry and Home Care enzyme development.

The two companies announced that a first project has been launched involving SlonoMax mutant libraries as part of a development process aiming at the functional optimisation of a specific enzyme.

Enzymes constitute an important ingredient in many modern household chemicals; their constant improvement is crucial to Henkel. Directed Evolution processes are used to optimise their properties. "In the past, we would generate huge collections of genetic variants of promising enzymes and screen them for desired features. With Sloning´s technology, we obtain libraries that precisely follow our design and contain all desired mutants. We expect to considerably increase our success rate and shorten development time", says Karl-Heinz Maurer, Director Research and Development of Henkel´s Laundry and Home Care division.

Sloning´s CEO Heinz Schwer explains: "Our genetic engineering platform allows to introduce selected alternative codons, leading to only those mutations the scientist actually wanted. This gives researchers additional freedom in setting up their experiments. We are happy to count Henkel among our customers. This underscores the added value SlonoMax libraries provide to any directed evolution process."

About Sloning Sloning BioTechnology GmbH specializes in the production of highly diverse and precisely engineered gene libraries. Sloning´s superior genetic libraries are essential in screening for new and improved therapeutic or industrial proteins. At the heart is its core technology, Slonomics®, a patented genetic engineering platform using sets of double stranded DNA triplets. Sloning is an investment holding of the listed venture capital company Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG (DEWB).

About Henkel Headquartered in Düsseldorf / Germany, Henkel KGaA has about 55,000 employees worldwide and counts among the most internationally aligned German-based companies in the global marketplace. People in approximately 125 countries around the world trust in brands and technologies from Henkel.

CONTACT: Sloning Headquarter Dr. Heinz Schwer, CEO +49 89 80 90 95 - 0 h.schwer@sloning.com

or

Sloning North America Garry Merry, Business Development 1 510-287-6600 g.merry@sloning.com

@@start.t2@@end of announcement                                                 euro adhoc
--------------------------------------------------------------------------------@@end@@

ots Originaltext: Deutsche Effecten- und Wechsel-Beteiligungsges. AG
Im Internet recherchierbar: http://www.presseportal.ch

Further inquiry note:
Marco Scheidler
DEWB AG
Tel.: +49 (0) 3641 573-3600
E-Mail: marco.scheidler@dewb-vc.com

Branche: Financial & Business Services
ISIN:      DE0008041005
WKN:        804100
Index:    CDAX, Classic All Share, Prime All Share
Börsen:  Frankfurt / regulated dealing/prime standard
              Berlin / free trade
              Stuttgart / free trade
              München / free trade



Weitere Meldungen: Deutsche Effecten- und Wechsel-Beteiligungsges. AG

Das könnte Sie auch interessieren: